NEWHALL CHARLES W III
SEC CIK 1005544 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| SUPN | SUPERNUS PHARMACEUTICALS, INC. | Dir | 124.1K | — | $2.00M | 15 | 2022-02-19 | 2026-02-24 |
Most active insiders at SUPN, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Khattar Jack A. | Pres, CEO, Dir | — | $7.72M |
| 2 | Bhatt Padmanabh P. | CSO, SVP of IP | — | $5.42M |
| 3 | NEWHALL CHARLES W III | Dir | — | $1.27M |
| 4 | Mottola Frank | SVP, Chief Tech. Ops. Off | — | $1.10M |
| 5 | GEMAYEL GEORGES | Dir | — | $1.00M |
| 6 | Horich William Todd | SVP, Commercial Ops | — | $483.8K |
| 7 | Hudson Frederick M. | Dir | — | $271.7K |
| 8 | Sensenig Bethany | Dir | — | $228.3K |
| 9 | Rubin Jonathan | SVP, Chief Medical Off | — | — |
| 10 | Barlow Carrolee | Dir | — | — |
Transactions 15
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-02-25 | 2026-02-24 | SUPN | SUPERNUS PHARMACEUTICALS, INC. | NEWHALL CHARLES W III | Dir | A - Grant | $0.00 | +4,475 | 124.1K | +4% | $0 |
| D | 2025-11-24 | 2025-11-21 | SUPN | SUPERNUS PHARMACEUTICALS, INC. | NEWHALL CHARLES W III | Dir | M - OptEx | $12.98 | +15.0K | 119.6K | +14% | +$194.7K |
| M | 2025-10-10 | 2025-10-09 | SUPN | SUPERNUS PHARMACEUTICALS, INC. | NEWHALL CHARLES W III | Dir | S - Sale | $50.77 | -25.0K | 105.8K | -19% | -$1.27M |
| 2025-08-29 | 2025-08-27 | SUPN | SUPERNUS PHARMACEUTICALS, INC. | NEWHALL CHARLES W III | Dir | S - Sale | $45.01 | -3,588 | 129.6K | -3% | -$161.5K | |
| 2025-08-27 | 2025-08-25 | SUPN | SUPERNUS PHARMACEUTICALS, INC. | NEWHALL CHARLES W III | Dir | S - Sale | $45.00 | -1,000 | 133.2K | -0.7% | -$45.0K | |
| 2025-08-26 | 2025-08-22 | SUPN | SUPERNUS PHARMACEUTICALS, INC. | NEWHALL CHARLES W III | Dir | S - Sale | $45.00 | -1,412 | 134.2K | -1% | -$63.5K | |
| D | 2025-02-24 | 2025-02-22 | SUPN | SUPERNUS PHARMACEUTICALS, INC. | NEWHALL CHARLES W III | Dir | A - Grant | $0.00 | +5,369 | 135.6K | +4% | $0 |
| D | 2024-11-12 | 2024-11-11 | SUPN | SUPERNUS PHARMACEUTICALS, INC. | NEWHALL CHARLES W III | Dir | M - OptEx | $9.13 | +20.0K | 141.0K | +17% | +$182.6K |
| D | 2024-11-12 | 2024-11-11 | SUPN | SUPERNUS PHARMACEUTICALS, INC. | NEWHALL CHARLES W III | Dir | S - Sale+OE | $36.24 | -10.7K | 130.3K | -8% | -$387.8K |
| D | 2024-02-27 | 2024-02-23 | SUPN | SUPERNUS PHARMACEUTICALS, INC. | NEWHALL CHARLES W III | Dir | A - Grant | $0.00 | +3,886 | 121.0K | +3% | $0 |
| D | 2023-11-20 | 2023-11-16 | SUPN | SUPERNUS PHARMACEUTICALS, INC. | NEWHALL CHARLES W III | Dir | M - OptEx | $9.24 | +7,457 | 119.6K | +7% | +$68.9K |
| D | 2023-11-20 | 2023-11-16 | SUPN | SUPERNUS PHARMACEUTICALS, INC. | NEWHALL CHARLES W III | Dir | S - Sale+OE | $28.01 | -2,500 | 117.1K | -2% | -$70.0K |
| D | 2023-02-24 | 2023-02-22 | SUPN | SUPERNUS PHARMACEUTICALS, INC. | NEWHALL CHARLES W III | Dir | A - Grant | $0.00 | +3,882 | 112.1K | +4% | $0 |
| D | 2022-12-30 | 2022-12-28 | SUPN | SUPERNUS PHARMACEUTICALS, INC. | NEWHALL CHARLES W III | Dir | M - OptEx | $7.90 | +8,722 | 110.5K | +9% | +$68.9K |
| D | 2022-02-23 | 2022-02-19 | SUPN | SUPERNUS PHARMACEUTICALS, INC. | NEWHALL CHARLES W III | Dir | A - Grant | $0.00 | +4,222 | 101.7K | +4% | $0 |
Purchase Sale Sale after option exercise All abbreviations